Background: Acinetobacter baumannii (AB) is increasingly becoming a clinically relevant
organism due to the rising number of associated nosocomial infections. The therapeutic …

Acinetobacter baumannii is an opportunistic pathogen that poses an increasing threat in the
health-care community. Colistin is one of the promising options for treatment of multidrug …

Background: Nosocomial infection caused by Acinetobacter baumannii has emerged as a
serious problem world-wide. Finding the suitable drug is an important priority. The aim of this …

Colistin is one of the most effective alternatives for treating Acinetobacter baumannii
infections. The aim of this study was to determine colistin resistance and heteroresistance …

Introduction Acinetobacter baumannii is a gram-negative, opportunistic pathogen
responsible for resistant nosocomial infections especially in the intensive care units (ICUS) …

Background and Aim: Colistin is increasingly being used as a “last-line” therapy to treat
infections caused by multidrug-resistant (MDR) Acinetobacter baumannii isolates, when …

Purpose: To evaluate the outcomes of the patients who were infected with colistin-only-
susceptible (COS) Acinetobacter baumannii and treated with either colistin monotherapy or …

Objectives To describe colistin-resistant Acinetobacter baumannii isolates in Cape Town,
South Africa. Methods A. baumannii isolates identified on Vitek 2 Advanced Expert System …

Objectives Colistin resistance rates are rising globally among multidrug-resistant Gram-
negative bacilli, including Acinetobacter baumannii (A. baumannii). A new type of resistance …

BACKGROUND: In recent years there has been an increase in life-threatening infections
caused by Acinetobacter baumannii with multiple antibiotic resistance, which has lead to the …